Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.45 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.45 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 3/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14627980 | 0.81 | TSHR (0.71) | TSHRGAAMAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL16002861 | 0.80 | TSHR (0.59) | TSHRGAAMAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL4079342 | 0.80 | TSHR (0.69) | TSHRGAAMAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL5804697 | 0.80 | TSHR (0.58) | TSHRGAAMAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL16000480 | 0.78 | TSHR (0.56) | TSHRGAAMAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL3455111 | 0.78 | SLC6A2 (0.64) | TSHRGAAMAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL17594997 | 0.77 | TSHR (0.66) | TSHRGAAMAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL3455617 | 0.77 | TSHR (0.58) | TSHRGAAMAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL8061129 | 0.77 | TSHR (0.70) | TSHRGAAMAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL5139469 | 0.77 | TSHR (0.66) | TSHRGAAMAPK1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802119-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802119-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8541581-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541581-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120088738-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS ,INC (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088738-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS ,INC (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2010118159-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088738-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, CES1 | TSHR 1387/4885GAA 671/4885MAPK1 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.